Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
- the REMAP-CAP Investigators
- Ministry of National Guard Health Affairs (MNGHA)
- King Saud bin Abdulaziz University for Health Sciences
- Imperial College London
- Imperial College Healthcare NHS Trust
- Utrecht University
- University College Dublin
- Monash University
- Alfred Health
- University of British Columbia
- Hôpital Raymond Poincaré
- University Versailles Saint Quentin and University Paris Saclay
- ANR-18-RHUS60004
- University of Oxford
- Medical Research Institute of New Zealand
- Berry Consultants
- University of Toronto
- University of Bristol
- University Hospitals Bristol and Weston NHS Foundation Trust
- Friedrich Schiller University Jena
- Global Coalition for Adaptive Research
- Amsterdam University Medical Centers
- Auckland District Health Board
- NHS Blood and Transplant
- Sunnybrook Health Sciences Centre
- Canadian Critical Care Trials Group
- University of Pittsburgh
- University of Antwerp
- National Intensive Care Surveillance-Mahidol Oxford Research Unit
- University College London
- Université de Sherbrooke
- Peter Munk Cardiac Centre
- University of California at Los Angeles
- Fiona Stanley Hospital
- St John of God Health Care
- University of Western Australia
- Queen's University Belfast
- Royal Victoria Hospital Belfast
- Middlemore Hospital
- Intensive Care National Audit and Research Centre
- University of Auckland
- University of Sydney
- Royal Prince Alfred Hospital
- Guy's and St Thomas' NHS Foundation Trust
- King's College London
- Royal Melbourne Hospital
- The University of Melbourne at the Peter Doherty Institute for Infection and Immunity
- Université Laval
- Radboud University Nijmegen
- University of Manitoba
Research output: Contribution to journal › Article › peer-review
77
Citations
(Scopus)